LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Moderate Buy” by Brokerages

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $56.40.

Several equities analysts have recently issued reports on the company. Zacks Research lowered LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research report on Monday, December 15th. Finally, Wall Street Zen upgraded shares of LENZ Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday.

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors have recently made changes to their positions in the stock. Quarry LP acquired a new position in LENZ Therapeutics in the third quarter valued at about $27,000. Bfsg LLC bought a new stake in shares of LENZ Therapeutics in the 3rd quarter valued at about $30,000. Osaic Holdings Inc. raised its position in shares of LENZ Therapeutics by 2,146.2% in the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after acquiring an additional 1,116 shares during the period. Tower Research Capital LLC TRC boosted its stake in LENZ Therapeutics by 51.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock worth $41,000 after acquiring an additional 477 shares during the last quarter. Finally, SBI Securities Co. Ltd. boosted its stake in LENZ Therapeutics by 9,235.3% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,587 shares of the company’s stock worth $74,000 after acquiring an additional 1,570 shares during the last quarter. 54.32% of the stock is owned by institutional investors and hedge funds.

LENZ Therapeutics Price Performance

Shares of LENZ Therapeutics stock opened at $13.32 on Monday. The firm has a 50 day simple moving average of $15.86 and a 200 day simple moving average of $27.78. LENZ Therapeutics has a fifty-two week low of $11.48 and a fifty-two week high of $50.40. The firm has a market cap of $416.66 million, a P/E ratio of -6.22 and a beta of 0.52.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.